Tony Chan

Tony serves as an adjunct professor at Georgetown Law School where he instructs on M&A law. He is also active in the community, serving on the steering committee for the Corporate and Securities section of the DC Bar and on the boards of the Arlington Arts Center and the Harvard Law School Association of DC.

Tony also maintains an active pro bono practice, serving as counsel to a number of nonprofit organizations, including Aequitas, APAI Vote, Rebuilding Together Philadelphia, the Philadelphia Film Society, and Kangu, in addition to a number of charter schools, including Rocketship Education and North Star.

Tony has been recognized for his life sciences and M&A work by a number of notable publications, including The Legal 500 US, Law360, IFLR1000, and Legal Media Group. In particular, Law360 highlighted his work in navigating the complex life sciences industry and key partnership negotiations between biotechnology and drug companies.

Life Sciences

• Represented Celgene Corporation on numerous transactions, including its
  • collaboration with Jounce Therapeutics, Inc. and related equity investment;
  • collaboration with Juno Therapeutics, Inc. and a related acquisition of a 10% stake for US$1 billion;
  • collaboration with Nurix, Inc.;
  • multiple collaborations with Sutro BioPharma;
  • multiple collaborations with Forma Therapeutics Holdings, LLC;
  • collaboration with OncoMed;
  • investment in Epizyme, Inc.; and
  • acquisition of Avila Therapeutics for US$350 million in cash, plus up to an additional US$575 million in contingent value rights.
• Represented Ipsen S.A. in connection with its acquisition of global oncology assets from Merrimack Pharmaceuticals for up to US$1 billion.
• Represented Ferring Pharmaceuticals on its
  • acquisition of Cytokine PharmaSciences Inc. and Controlled Therapeutics (Scotland) Ltd.;
  • acquisition of Lysteda, a pharmaceutical product indicated for the treatment of menorrhagia, from Xanodyne Pharmaceuticals, Inc.;
  • acquisition of DDAVP from Sanofi;
  • acquisition of the global rights to Milprosa from Teva Women’s Health, Inc.; and
  • acquisition of two phase III ready orthobiologic product candidates from BioSurface Engineering Technologies Inc.
• Represented R-Pharm US in its acquisition of the breast cancer drug Ixempra from Bristol-Myers Squibb.
• Represented Orexo AB in its sale of its rights to Abstral in the United States to Galena Biopharma, Inc.
• Represented Lumara Health Inc. in its sale in two separate transactions for up to US$1.1 billion.
• Represented Intezyne, a clinical-stage company developing novel anti-cancer therapies, in a series of financing transactions.
• Represented Cornerstone Therapeutics in its acquisition of Cardiokine Inc., a specialty pharmaceutical company focused on developing products for cardiovascular indications.
• Represented Paul Capital Partners in its sale of Timm Medical Technologies, Inc. to Actient Pharmaceuticals.
• Represented Topotarget A/S in its sale of the pharmaceutical products Savene to SpePharm Holding B.V. and Totect to Apricus Biosciences.
• Represented Covance Inc. in its acquisition of the Gene Expression Laboratory from Merck.
• Represented Tekla Capital Management in a broad range of investments in private biotechnology companies.

Financial Services

• Represented Guggenheim Investments in its acquisition of Accretive Asset Management LLC.
• Represented Ameriprise Financial in its sale of the retail custodial and transfer agency businesses and acquisition of Emerging Global Advisers, LLC.
• Represented Innovatus Capital Partners in its formation and establishment of operations.
• Represented Marble Point Credit Management in its acquisition of American Capital CLO Management, LLC.
• Represented Pretium Capital Management in its acquisition of Valcour Capital Management, LLC.
• Represented RCS Capital Corporation in its sale of Hatteras Funds, LLC to Raleigh Acquisition, LLC.
• Represented William Blair & Company in its acquisition of hedge-fund-of-funds firm Guidance Capital, LLC.
• Represented Horizons ETFs Management (USA) LLC is its acquisition of Recon Capital Management, LLC.
• Represented Fifth Street CLO Management in its sale of Fifth Street CLO Management LLC to Newstar Financial, Inc.
• Represented Manulife Asset Management in its acquisition of Optique Capital Management, LLC.
• Represented Ashmore in its acquisition of Dolomite Capital Management, LLC.
• Represented FSI Capital in its acquisition of ACA's asset management business.
• Represented State Street Global Advisors in its sale of Shott Capital Management to Hamilton Lane Advisors.
• Represented Dividend Capital Advisors in its sale of certain assets of Virtus Investment Partners.
• Represented Ticonderoga in its acquisitions of Reynders, Gray & Co. and Soleil Securities.
• Represented A10 Capital, LLC in its sale of a minority interest to H.I.G. Capital.

Technology

• Represented Stripes Group, a leading growth equity firm, in a number of its investments, including in Art.com, Audionetwork, BlackTux, Blue Apron, BookMyShow, Califia Farms, Craftsy, eMarketer, Flatiron Health, Gimlet Media, GoFundMe, GrubHub, Kareo, Ketra Lighting, MyWebGrocer, Netbiscuits, Pond5, Refinery29, Reformation, Remitly, Sandata, SPINS, Stella & Chewy’s, Turtle Beach, Udemy, and Upwork.
• Represented Turtle Beach Corporation in its acquisition of Parametric Sound Corporation.
• Represented MyWebGrocer, a provider of digital grocery solutions, in its sale to HGGC.
• Represented the management team of Getty Images, Inc. in the US$2.4 billion acquisition of Getty Images by Hellman & Friedman.
• Represented Gilat Satellite Networks in its sale of SpaceNet, Inc. to SageNet.
• Represented Versa Capital Management, Inc. in its acquisition of Allen-Vanguard Corporation.
• Represented the special committee of the board of directors of XO Holdings, Inc. in connection with the acquisition of XO Holdings by ACF Industries Holding Corp., an entity wholly owned by Carl Icahn.

*Matters were handled prior to joining Morgan Lewis.